$NVS buying $RNA $72 per share - $12B https://t.co/K5REunIdu9
$NVS for $RNA. Here it comes, per Bloomberg https://t.co/iQg2xHGsIT
$RNA - del-zota BLA submission pushed back to Q1 '26 from Q4 '25... "to ensure the FDA receives additional data to support the chemistry, manufacturing, and controls (CMC) package at time of submission." https://t.co/aLbJxhmnFU
The gov't shutdown means FDA is not accepting drug-approval applications. I did quick scan of potentially affected drug makers, defined by me as companies that have guided to filings by EOY. $VRDN $RNA $MRNA $COGT $VERA Any others, add in replies.
Robert Blum should call Sarah Boyce tonight. "Sarah, this is Robert. Hey, let me tell you how this goes, from experience...." $CYTK $RNA
The $RNA takeover story has unraveled.
$RNA at Cantor today, on acquisition chatter... Question – But there has been rumors of acquisition interest in your company. What, if anything, do you want to share about that? Answer – Yeah. You know, look, I would say we're now entering into an era, another Taylor Swift pun. We're now entering into an era where we're probably going to have a lot of rumors about us and around the interest in Avidity. Well, we have three drugs that we're looking to launch in a 12-month period. Two of those drugs, we believe are multibillion-dollar indications. So extremely valuable. And I expect here, there's going to be lots of rumors about us. What I will say is for us as a team, we are 100% focused on delivering to patients and getting our drugs to patients as quickly as possible, because we believe, yeah, as does the patient community, the clinical community, and I think starting the investor community now as well and I know you're a big supporter that we have the potential to make a profound impact in tens of thousands of people's lives, and that's what we're focused on. h/t Alphasense
Backing up @mroliverbarnes et al reporting here, I heard same $NVS for $RNA chatter a few weeks ago. I wasn't able to confirm enough to report on it, unlike the FT folks, so well done by them. Deal makes a lot of sense for both sides, if it happens.
Novartis $NVS reportedly considering acquisition of Avidity Biosciences $RNA - Financial Times.
